Skip to main content
Premium Trial:

Request an Annual Quote

Screening Technology Company IntelliCyt Raises $8M

NEW YORK (GenomeWeb News) – Screening technology firm IntelliCyt today said it raised $8 million in a financing round.

New investor Arboretum Ventures led the financing and was joined by existing investors Prolog Ventures, Verge Fund, and New Mexico Community Capital.

Tim Petersen and George Dunbar from Arboretum Ventures are joining IntelliCyt's board in connection to the financing, the Albuquerque, NM-based company said.

"We are seeing a significant acceleration in customer adoption and these funds will enable the company to expand our commercial efforts globally, grow manufacturing capacity, and expand our suite of reagent kits," IntelliCyt President and CEO R. Terry Dunlay said in a statement.

The company was founded in 2006 and develops high-throughput cell- and bead-based screening technologies. Its platform called the iQue Screener allows for microvolume sample delivery and rapid processing, the firm said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.